IQVIA has conducted over 25 radiopharmaceutical clinical trials across 40 countries, activating 800+ sites and enrolling 5,000+ patients. Radioligand therapies (RLTs) target tumor markers with precision, sparing healthy cells, and are advancing beyond prostate and neuroendocrine cancers into rare and aggressive indications. Trials face unique challenges, including limited manufacturing sites, short half-lives of isotopes, regulatory variations, and patient recruitment hurdles. IQVIA applies best practices in logistics, site feasibility, partner management, and regulatory compliance to streamline execution, helping biopharma accelerate development and expand access to innovative cancer therapies.

Join for free to read